Table 2.
Clinico-pathological information and quantitative methylation data for sputum samples
| Sputum sample no. | Age | Gender | Diagnosis | Stage | m3-OST-2 | mRASSF1A | mP16 | mAPC |
|---|---|---|---|---|---|---|---|---|
| CWDNA10 | 71 | Male | No lung cancer | NA | 0 | 0 | 0 | 0 |
| CWDNA11 | 68 | Female | No lung cancer | NA | 0 | 0 | 0 | 0 |
| CWDNA14 | 80 | Male | No lung cancer | NA | 0 | 0 | 0 | 0 |
| CWDNA15 | 54 | Female | No lung cancer | NA | 0 | 0 | 3.99 | 0.28 |
| CWDNA16 | 63 | Female | No lung cancer | NA | 3.21 | 0.42 | 0 | 0 |
| CWDNA17 | 78 | Male | No lung cancer | NA | 0 | 0 | 0 | 0 |
| CWDNA20 | 64 | Male | No lung cancer | NA | 0 | 0 | 0 | 0 |
| CWDNA22 | 71 | Male | No lung cancer | NA | 0 | 0 | 7.67 | 0 |
| CWDNA23 | 54 | Female | No lung cancer | NA | 0 | 0 | 0 | 0 |
| CWDNA26 | 79 | Male | No lung cancer | NA | 0 | 0 | 0 | 0 |
| CWDNA27 | 66 | Male | No lung cancer | NA | 0 | 1.12 | 0 | 0 |
| CWDNA29 | 52 | Male | No lung cancer | NA | 0 | 0 | 0 | 0 |
| CWDNA33 | 54 | Male | No lung cancer | NA | 0 | 0 | 0 | 0 |
| CWDNA35 | 63 | Female | No lung cancer | NA | 0 | 0 | 0 | 0 |
| CWDNA36 | 80 | Male | No lung cancer | NA | 0 | 0 | 0 | 0 |
| CWDNA37 | 69 | Male | No lung cancer | NA | 0 | 0 | 0 | 0 |
| CWDNA39 | 54 | Male | No lung cancer | NA | 0 | 0 | 0 | 0 |
| CWDNA24 | 45 | Female | Breast carcinoma | NA | 0 | 0 | 0 | 0 |
| CWDNA2 | 77 | Male | No lung cancer | NA | 0 | 0 | 0 | 0 |
| CWDNA6 | 50 | Female | No lung cancer | NA | 0.85 | 0 | 0 | 0 |
| CWDNA8 | 61 | Female | No lung cancer | NA | 0 | 0 | 0 | 0 |
| CWDNA12 | 73 | Male | Prior lung cancer* | ND | 0 | 0 | 0 | 0 |
| CWDNA18 | 68 | Male | Prior lung cancer* | IA | 0 | 0 | 0 | 0 |
| CWDNA30 | 73 | Male | Prior lung cancer* | IB | 2.98 | 0 | 0 | 0 |
| CWDNA1 | 58 | Male | Prior lung cancer* | IIIA | 0 | 0 | 0 | 0 |
| CWDNA3 | 81 | Male | Squamous cell carcinoma | IIB | 0 | 0 | 512.86 | 0 |
| CWDNA4 | 71 | Male | Adenocarcinoma | IV | 0 | 159.59 | 0 | 5.4 |
| CWDNA5 | 79 | Male | Squamous cell carcinoma | IIIA | 33.11 | 125.6 | 0 | 0.32 |
| CWDNA7 | 55 | Male | Adenocarcinoma | IV | 100 | 0 | 0 | 0 |
| CWDNA9 | 68 | Male | Squamous cell carcinoma | IIIA | 0 | 0 | 0 | 0 |
| CWDNA13 | 83 | Male | Adenocarcinoma | IV | 0 | 0 | 0 | 0 |
| CWDNA19 | 78 | Male | Squamous cell carcinoma | IIIA | 0 | 50.84 | 29.32 | 4.86 |
| CWDNA21 | 52 | female | Adenocarcinoma | IA | 0 | 0 | 0 | 0 |
| CWDNA25 | 77 | Male | Squamous cell carcinoma | IIIB | 0 | 0 | 0 | 0 |
| CWDNA31 | 39 | Male | Adenocarcinoma | IIB | 4.62 | 36.73 | 14.45 | 0.91 |
| CWDNA32 | 68 | Male | Squamous cell carcinoma | IA | 13.49 | 0 | 0 | 0 |
| CWDNA38 | 65 | Male | Squamous cell carcinoma | ND | 0 | 35.48 | 0 | 0 |
| CWDNA40 | 73 | Male | Squamous cell carcinoma | IV | 0.42 | 0 | 0 | 0 |
All the controls were free of lung cancer at the time the sputum was collected. Four contol patients (*) had lung cancer >1 year before the sputum was collected. Control patient CW24 had breast cancer at the time the sputum was collected. NA, not applicable; ND, information not available.